Mollie E. Moran

1.9k total citations
42 papers, 1.5k citations indexed

About

Mollie E. Moran is a scholar working on Genetics, Pathology and Forensic Medicine and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Mollie E. Moran has authored 42 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 38 papers in Genetics, 22 papers in Pathology and Forensic Medicine and 12 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Mollie E. Moran's work include Chronic Lymphocytic Leukemia Research (38 papers), Lymphoma Diagnosis and Treatment (22 papers) and Advanced Breast Cancer Therapies (12 papers). Mollie E. Moran is often cited by papers focused on Chronic Lymphocytic Leukemia Research (38 papers), Lymphoma Diagnosis and Treatment (22 papers) and Advanced Breast Cancer Therapies (12 papers). Mollie E. Moran collaborates with scholars based in United States and Switzerland. Mollie E. Moran's co-authors include Thomas S. Lin, Michael R. Grever, Nyla A. Heerema, John C. Byrd, David Lucas, Margaret S. Lucas, Gerard Lozanski, Kristie A. Blum, John C. Byrd and Beth Fischer and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Clinical Pharmacology & Therapeutics.

In The Last Decade

Mollie E. Moran

39 papers receiving 1.4k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Mollie E. Moran United States 15 920 677 475 428 354 42 1.5k
Beth Fischer United States 9 426 0.5× 309 0.5× 298 0.6× 328 0.8× 161 0.5× 28 829
Steven Novick United States 16 362 0.4× 178 0.3× 819 1.7× 437 1.0× 142 0.4× 28 1.4k
Alberto Bessudo United States 18 258 0.3× 359 0.5× 517 1.1× 609 1.4× 159 0.4× 70 1.2k
Paweł Robak Poland 19 343 0.4× 269 0.4× 539 1.1× 372 0.9× 186 0.5× 86 1.1k
Jean Powers Canada 17 270 0.3× 356 0.5× 561 1.2× 556 1.3× 102 0.3× 32 1.3k
Nikhil Mukhi United States 7 250 0.3× 283 0.4× 398 0.8× 367 0.9× 159 0.4× 14 891
Hyeon Seok Eom South Korea 15 180 0.2× 671 1.0× 392 0.8× 590 1.4× 239 0.7× 58 1.3k
Saman Hewamana United Kingdom 16 533 0.6× 224 0.3× 461 1.0× 181 0.4× 307 0.9× 33 965
Toshiyuki Ohno Japan 19 389 0.4× 833 1.2× 154 0.3× 527 1.2× 302 0.9× 50 1.2k

Countries citing papers authored by Mollie E. Moran

Since Specialization
Citations

This map shows the geographic impact of Mollie E. Moran's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mollie E. Moran with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mollie E. Moran more than expected).

Fields of papers citing papers by Mollie E. Moran

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mollie E. Moran. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mollie E. Moran. The network helps show where Mollie E. Moran may publish in the future.

Co-authorship network of co-authors of Mollie E. Moran

This figure shows the co-authorship network connecting the top 25 collaborators of Mollie E. Moran. A scholar is included among the top collaborators of Mollie E. Moran based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mollie E. Moran. Mollie E. Moran is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Mansour, Anthony G., Ying Huang, Adam S. Kittai, et al.. (2024). Outcomes of Patients with Chronic Lymphocytic Leukemia Discontinuing Bruton Tyrosine Kinase Inhibitors Due to Adverse Effects. Blood. 144(Supplement 1). 4629–4629.
2.
Rogers, Kerry A., Ying Huang, Amy S. Ruppert, et al.. (2020). Three-Year Follow-up from a Phase 2 Study of Combination Obinutuzumab, Ibrutinib, and Venetoclax in Chronic Lymphocytic Leukemia. Blood. 136(Supplement 1). 9–10. 11 indexed citations
3.
Andritsos, Leslie A., James S. Blachly, Kerry A. Rogers, et al.. (2019). Classic hairy cell leukemia complicated by pancytopenia and severe infection: a report of 3 cases treated with vemurafenib. Blood Advances. 3(2). 116–118. 19 indexed citations
4.
Dawson, Keith, et al.. (2016). Managing Infusion-Related Reactions for Patients With Chronic Lymphocytic Leukemia Receiving Obinutuzumab. Clinical journal of oncology nursing. 20(2). E41–E48. 10 indexed citations
5.
Bain, Gretchen, Christopher D. King, Angelina M. Santini, et al.. (2010). Pharmacodynamics and Pharmacokinetics of AM103, a Novel Inhibitor of 5-Lipoxygenase-Activating Protein (FLAP). Clinical Pharmacology & Therapeutics. 87(4). 437–444. 25 indexed citations
6.
Woyach, Jennifer A., Thomas S. Lin, Margaret S. Lucas, et al.. (2009). A phase I/II study of rituximab and etanercept in patients with chronic lymphocytic leukemia and small lymphocytic lymphoma. Leukemia. 23(5). 912–918. 25 indexed citations
7.
Lin, Thomas S., Louie Naumovski, Philip Lecane, et al.. (2009). Effects of motexafin gadolinium in a phase II trial in refractory chronic lymphocytic leukemia. Leukemia & lymphoma. 50(12). 1977–1982. 16 indexed citations
8.
Lin, Thomas S., Amy S. Ruppert, Amy J. Johnson, et al.. (2009). Phase II Study of Flavopiridol in Relapsed Chronic Lymphocytic Leukemia Demonstrating High Response Rates in Genetically High-Risk Disease. Journal of Clinical Oncology. 27(35). 6012–6018. 178 indexed citations
9.
Phelps, Mitch A., Thomas S. Lin, Amy J. Johnson, et al.. (2008). Clinical response and pharmacokinetics from a phase 1 study of an active dosing schedule of flavopiridol in relapsed chronic lymphocytic leukemia. Blood. 113(12). 2637–2645. 128 indexed citations
10.
Moran, Mollie E., et al.. (2007). Nursing Guidelines for Managing Infections in Patients With Chronic Lymphocytic Leukemia. Clinical journal of oncology nursing. 11(6). 914–924. 3 indexed citations
11.
12.
Lin, Thomas S., Mitch A. Phelps, James T. Dalton, et al.. (2006). Flavopiridol Can Be Safely Dose Escalated in Relapsed CLL Patients: Achievement of Target Cmax Results in Improved Clinical Activity.. Blood. 108(11). 2845–2845. 4 indexed citations
13.
Lin, Thomas S., Margaret S. Lucas, Nyla A. Heerema, et al.. (2006). A Phase II Study of the TNF-α Inhibitor Etanercept and Thrice Weekly Rituximab in Relapsed CLL/SLL: Clinical Activity in the Absence of Del(17p13) Genomic Abnormalities.. Blood. 108(11). 2841–2841. 8 indexed citations
14.
Lin, Thomas S., Ian W. Flinn, Margaret S. Lucas, et al.. (2005). Filgrastim and alemtuzumab (Campath-1H) for refractory chronic lymphocytic leukemia. Leukemia. 19(7). 1207–1210. 26 indexed citations
15.
Marcucci, Guido, Wendy Stock, Guowei Dai, et al.. (2005). Phase I Study of Oblimersen Sodium, an Antisense to Bcl-2, in Untreated Older Patients With Acute Myeloid Leukemia: Pharmacokinetics, Pharmacodynamics, and Clinical Activity. Journal of Clinical Oncology. 23(15). 3404–3411. 112 indexed citations
16.
17.
Lozanski, Gerard, Nyla A. Heerema, Ian W. Flinn, et al.. (2004). Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions. Blood. 103(9). 3278–3281. 306 indexed citations
18.
Lin, Thomas S., et al.. (2004). Antibody therapy for chronic lymphocytic leukemia: a promising new modality. Hematology/Oncology Clinics of North America. 18(4). 895–913. 11 indexed citations
19.
Lin, Thomas S., James T. Dalton, Di Wu, et al.. (2004). Flavopiridol given as a 30-min intravenous (IV) bolus followed by 4-hr continuous IV infusion (CIVI) results in clinical activity and tumor lysis in refractory chronic lymphocytic leukemia (CLL). Journal of Clinical Oncology. 22(14_suppl). 6564–6564. 5 indexed citations
20.
Lin, Thomas S., Ian W. Flinn, Rama Modali, et al.. (2004). FCGR3A and FCGR2A polymorphisms may not correlate with response to alemtuzumab in chronic lymphocytic leukemia. Blood. 105(1). 289–291. 53 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Beth Fischer Breakdown of academic impact, for papers by Steven Novick Breakdown of academic impact, for papers by Alberto Bessudo Breakdown of academic impact, for papers by Paweł Robak Breakdown of academic impact, for papers by Jean Powers Breakdown of academic impact, for papers by Nikhil Mukhi Breakdown of academic impact, for papers by Hyeon Seok Eom Breakdown of academic impact, for papers by Saman Hewamana Breakdown of academic impact, for papers by Toshiyuki Ohno
Rankless by CCL
2026